AKRO
Akero Therapeutics, Inc.Company Information
- Company Name
- Akero Therapeutics, Inc.
- CIK
- CIK0001744659
- Category
- Large accelerated filer
- Ticker: Exchange
- AKRO: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- AKRO
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-03-27
- Last sale
- 2025-10-10
- Shares purchased (TTM)
- 250,000
- Shares sold (TTM)
- 1,106,067
Institutional Sentiment
- As of
- 2025-12-31
- Institutional shares owned
- 57
- Shares outstanding
- 82,008,267
- Ownership
- 0.00%
Earnings Market Reaction
- Filing date
- 2025-11-07
- Price on filing date
- —
- 1-month reaction
- 0.59%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 176 | 220 | 186 | 340 | 316 | 310 | 624 | 234 | 270 | 444 | 258 | 250 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 755 | 765 | 713 | 770 | 747 | 776 | 911 | 560 | 576 | 643 | 347 | 355 | ||||||
| Marketable Securities Current | 562 | 522 | 500 | 403 | 401 | 450 | 280 | 316 | 285 | 195 | 85 | 102 | ||||||
| Prepaid Expense And Other Assets Current | 17 | 22 | 27 | 27 | 30 | 16 | 8 | 10 | 21 | 4 | 4 | 4 | ||||||
| Marketable Securities Noncurrent | 250 | 344 | 442 | 55 | 70 | 88 | - | 19 | 58 | 19 | - | - | ||||||
| Property Plant And Equipment Net | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Other Assets Noncurrent | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Assets | 1,006 | 1,109 | 1,156 | 826 | 818 | 865 | 912 | 580 | 635 | 664 | 349 | 357 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable Current | 20 | 13 | 11 | 9 | 25 | 15 | 14 | 7 | 11 | 10 | 7 | 8 | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 48 | 60 | 42 | 40 | 43 | 31 | 30 | 19 | 28 | 22 | 17 | 19 | ||||||
| Loans Payable Current | - | - | - | - | - | - | - | - | 2 | - | - | - | ||||||
| Long Term Loans Payable | - | 22 | 29 | 35 | 35 | 35 | 35 | 25 | 23 | 25 | 25 | 10 | ||||||
| Derivative Liabilities Noncurrent | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Liabilities | 48 | 83 | 72 | 76 | 79 | 67 | 66 | 45 | 52 | 47 | 42 | 30 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 2,005 | 1,992 | 1,980 | 1,575 | 1,492 | 1,482 | 1,474 | 1,109 | 1,103 | 1,096 | 754 | 749 | ||||||
Stockholders Equity | ||||||||||||||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 2 | 1 | 1 | 1 | 2 | -0 | -0 | 0 | -1 | -0 | 0 | 0 | ||||||
| Stockholders Equity | 958 | 1,026 | 1,084 | 750 | 738 | 798 | 846 | 535 | 583 | 616 | 306 | 327 | ||||||
| Retained Earnings Accumulated Deficit | -1,049 | -967 | -897 | -826 | -756 | -683 | -627 | -574 | -519 | -479 | -448 | -422 | ||||||
| Liabilities And Stockholders Equity | 1,006 | 1,109 | 1,156 | 826 | 818 | 865 | 912 | 580 | 635 | 664 | 349 | 357 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | ||||||
| Common Stock Shares Issued | 80 | 80 | 80 | 72 | 70 | 69 | 69 | 56 | 56 | 56 | 47 | 47 | ||||||
| Shares Outstanding | 80 | 80 | 80 | 72 | 70 | 69 | 69 | 56 | 56 | 56 | 47 | 47 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAkero Therapeutics, Inc. (AKRO) — SEC Financial Statements & Analysis
Akero Therapeutics, Inc. (AKRO) is a pharmaceutical preparations company, incorporated in DE. Akero Therapeutics, Inc. trades on Nasdaq as: AKRO. Akero Therapeutics, Inc. (AKRO)'s most recent SEC filing is a Form 10-Q for the period ended 2025-09-30, filed with the SEC on 2025-11-07. Based on that filing, On profitability, Akero Therapeutics, Inc. posts a Return on Equity (ROE) of -34.53%, a Return on Assets (ROA) of -32.12%, and a Return on Invested Capital (ROIC) of -54.83%. Per share, it reports EPS of $-3.57, diluted EPS of $-3.57, free cash flow per share of $-3.05, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 23.44% year-over-year and EPS growth of 4.52% year-over-year. On the balance sheet, it maintains a current ratio of 15.83x, a quick ratio of 15.48x, working capital of $706.88M, a debt-to-equity ratio of 0.05x, a debt ratio of 0.05, an interest coverage ratio of -71.46x, free cash flow of $-250.17M (TTM), and net debt of $-176.03M. Figures sourced from SEC EDGAR.
- EPS TTM
- $-3.57
- ROE TTM
- -34.53%
- ROA TTM
- -32.12%
- Debt To Equity
- 0.05x
- Free Cash Flow TTM
- $-250.17M
Data as of 2025-09-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Akero Therapeutics, Inc. in?
Akero Therapeutics, Inc. (AKRO) operates in the Pharmaceutical Preparations industry.
What exchange does AKRO trade on?
Akero Therapeutics, Inc. (AKRO) trades on the Nasdaq.
Where is Akero Therapeutics, Inc. incorporated?
Akero Therapeutics, Inc. is incorporated in DE.
When was Akero Therapeutics, Inc. (AKRO)'s most recent SEC filing?
Akero Therapeutics, Inc. (AKRO)'s most recent SEC filing is a Form 10-Q for the period ended 2025-09-30, filed with the SEC on 2025-11-07.
What is AKRO's EPS (earnings per share)?
Akero Therapeutics, Inc. (AKRO)'s trailing twelve month EPS is $-3.57 as of 2025-09-30.
What is AKRO's ROE (return on equity)?
Akero Therapeutics, Inc. (AKRO)'s trailing twelve month Return on Equity (ROE) is -34.53% as of 2025-09-30.
What is AKRO's ROA (return on assets)?
Akero Therapeutics, Inc. (AKRO)'s trailing twelve month Return on Assets (ROA) is -32.12% as of 2025-09-30.
What is AKRO's ROIC (return on invested capital)?
Akero Therapeutics, Inc. (AKRO)'s trailing twelve month Return on Invested Capital (ROIC) is -54.83% as of 2025-09-30.